PMID: 9749829Sep 28, 1998Paper

Adenosine 5'-diphosphate as a factor in platelet aggregation induced by human plasma remnant lipoproteins

Life Sciences
A R SaniabadiM Nakashima

Abstract

The action of lipoprotein lipase on chylomicrons (CM) and very low density lipoproteins (VLDL) produces remnant lipoproteins (RLP) which are rich in triglycerides, cholesterol and apolipoprotein E (apo E). Apo E serves as a ligand for uptake of RLP by macrophages, platelets, endothelial cells and other cells expressing the LDL-receptor or the remnant receptor, thus having a major role in the clearance of plasma cholesterol and triglycerides, but at the same time, uptake of apo E-bearing RLP can profoundly alter the physiology of these cells and promote atherosclerosis. Like RLP, blood platelets also have roles in atherosclerosis and thrombosis, hence it is likely that RLP influence platelet activity as well. RLP derived from normal human plasma VLDL and CM were prepared using two monoclonal antibodies, anti-apo B-100 (JI-H) and anti-apo A-I (H-12) coupled to Sepharose 4B gel to form an immunoaffinity column. Lipoproteins containing apo B-100 including VLDL and LDL adsorb to (JI-H)-gel, while CM and HDL with apo A-I adsorb to (H-12)-gel. The particles in the unbound fraction (RLP) are rich in apo B-48, apo E and apo B-100 containing particles with multiple molecules of apo E. The RLP fraction with a total triglyceride of 14+/-3....Continue Reading

References

Feb 1, 1975·Annals of Internal Medicine·J MorganrothD S Fredrickson
Sep 1, 1979·Circulation·D B Zilversmit
Sep 1, 1977·British Medical Bulletin·G V Born
Jul 1, 1976·Circulation·I S Wright
Jan 1, 1991·Pharmacology & Therapeutics·W J Thompson
Jan 11, 1991·Pharmacology·M A OriowoR R Ruffolo
Apr 1, 1985·Journal of the American College of Cardiology·W H GaaschO H Bing
May 1, 1985·Thrombosis Research·A R SaniabadiC D Forbes
Feb 21, 1974·The New England Journal of Medicine·A C CarvalhoR S Lees
Jan 1, 1983·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J P KaneR J Havel
Apr 15, 1995·Thrombosis Research·R KnöflerA Takada
Jun 1, 1995·The New England Journal of Medicine·R J Havel, E Rapaport
Nov 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J H RappJ P Kane
Apr 1, 1994·Current Opinion in Lipidology·R J Havel
Dec 31, 1993·Clinica Chimica Acta; International Journal of Clinical Chemistry·K NakajimaE Campos
Jan 1, 1993·American Heart Journal·I I Surya, J W Akkerman
Jul 1, 1993·Journal of Bioluminescence and Chemiluminescence·A R Saniabadi, M Nakano
Jan 1, 1994·Journal of Atherosclerosis and Thrombosis·K NakajimaT Murase

❮ Previous
Next ❯

Citations

Mar 24, 2007·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masayuki Yoshida
Jul 5, 2001·Biochemical and Biophysical Research Communications·A M SawkaT O'Brien
Aug 1, 2006·Pathophysiology of Haemostasis and Thrombosis·Rasaq Olufadi, Christopher D Byrne

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.